Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt Sells 876,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt sold 876,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the completion of the transaction, the director now directly owns 22,179,358 shares of the company’s stock, valued at approximately $262,160,011.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Roivant Sciences Stock Down 0.8 %

Shares of NASDAQ:ROIV opened at $11.48 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences Ltd. has a 1 year low of $8.24 and a 1 year high of $13.24. The stock has a market capitalization of $8.48 billion, a P/E ratio of 2.27 and a beta of 1.25. The stock has a 50-day simple moving average of $11.50 and a 200-day simple moving average of $11.08.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. The firm had revenue of $55.10 million during the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. Roivant Sciences’s quarterly revenue was up 155.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) EPS. Equities analysts forecast that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Piper Sandler upped their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.39.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mutual of America Capital Management LLC boosted its stake in shares of Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after buying an additional 1,142 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Roivant Sciences by 23.2% during the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after buying an additional 1,603 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Roivant Sciences during the 2nd quarter valued at approximately $34,000. DNB Asset Management AS boosted its stake in shares of Roivant Sciences by 6.4% during the 2nd quarter. DNB Asset Management AS now owns 56,022 shares of the company’s stock valued at $592,000 after buying an additional 3,386 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences during the 2nd quarter valued at approximately $36,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.